UK markets open in 4 hours 56 minutes
  • NIKKEI 225

    27,754.36
    +60.71 (+0.22%)
     
  • HANG SENG

    21,487.39
    +265.23 (+1.25%)
     
  • CRUDE OIL

    74.92
    +0.81 (+1.09%)
     
  • GOLD FUTURES

    1,887.50
    +8.00 (+0.43%)
     
  • DOW

    33,891.02
    -34.99 (-0.10%)
     
  • BTC-GBP

    18,996.28
    -93.59 (-0.49%)
     
  • CMC Crypto 200

    525.17
    +0.03 (+0.01%)
     
  • ^IXIC

    11,887.45
    -119.50 (-1.00%)
     
  • ^FTAS

    4,303.90
    -35.81 (-0.83%)
     

RAF Proto Oncogene Serine, Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

ReportLinker
ReportLinker

Summary. RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene.

New York, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "RAF Proto Oncogene Serine, Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" - https://www.reportlinker.com/p06380660/?utm_source=GNW
Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) pipeline Target constitutes close to 22 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 3, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively. Report covers products from therapy areas Oncology and Genetic Disorders which include indications Solid Tumor, Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Liver Cancer, Lung Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Unspecified Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Anaplastic Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Blood Cancer, Cervical Cancer, Chondrosarcoma, Chordoma, Craniopharyngioma, Endometrial Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioblastoma Multiforme (GBM), Glioma, Head And Neck Cancer Squamous Cell Carcinoma, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Kidney Cancer (Renal Cell Cancer), Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Liposarcoma, Low-Grade Glioma, Malignant Glioma, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Pancreatic Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myelofibrosis, Non-Small Cell Lung Carcinoma, Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Prostate Cancer, Rectal Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Rhabdomyosarcoma, Sarcomas, Soft Tissue Sarcoma, Transitional Cell Cancer (Urothelial Cell Cancer) and Triple-Negative Breast Cancer (TNBC).

The latest report, outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The report provides a snapshot of the global therapeutic landscape for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
- The report reviews RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics

Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Read the full report: https://www.reportlinker.com/p06380660/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001